Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.


Free Access

Role of Aberrant Glycosylation of IgA1 Molecules in the Pathogenesis of IgA Nephropathy

Mestecky J.a, b, g · Tomana M.b · Moldoveanu Z.a · Julian B.A.a, b · Suzuki H.a, f · Matousovic K.a, g · Renfrow M.B.c · Novak L.d · Wyatt R.J.e · Novak J.a

Author affiliations

Departments of aMicrobiology, bMedicine, cBiochemistry/Molecular Genetics, and dPathology, University of Alabama at Birmingham, Birmingham, Ala., and eUniversity of Tennessee Health Science Center, Memphis, Tenn., USA; fJuntendo University School of Medicine, Tokyo, Japan; gCharles University, Schools of Medicine, Prague and Pilsen, Czech Republic

Corresponding Author

Jiri Mestecky, MD, PhD

Department of Microbiology, University of Alabama at Birmingham

Box 1 845, 19th Street South

Birmingham, AL 35294-2170 (USA)

Tel. +1 205 934 2225, Fax +1 205 934 3894, E-Mail mestecky@uab.edu

Related Articles for ""

Kidney Blood Press Res 2008;31:29–37

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Studies of the properties of immune complexes (IC) in the circulation, urine, and mesangium of IgA nephropathy (IgAN) patients have provided data relevant to the pathogenesis of this disease. IC contain predominantly polymeric IgA1 molecules which are deficient in galactose (Gal) residues on O-linked glycan chains in the hinge region (HR) of their heavy (H) chains. As a result of this aberrancy, a novel antigenic determinant(s) involving N-acetylgalactosamine (GalNAc) and perhaps sialic acid (SA) of O-linked glycans is generated and recognized by naturally occurring GalNAc-specific antibodies. Thus, IC in IgAN consist of Gal-deficient IgA1 molecules as an antigen, and GalNAc-specific IgG and/or IgA1 as an antibody. IgG antibodies to Gal-deficient IgA1 are probably induced by cross-reactive microbial antigens; they are present at variable levels not only in humans with or without IgAN but also in many phylogenetically diverse vertebrate species. Incubation of human mesangial cells with IC from sera of IgAN patients indicated that stimulation of cellular proliferative activity was restricted to the large (>800 kDa) complexes. These findings suggest that experimental approaches that prevent the formation of large Gal-deficient IgA1-IgG IC may be applied ultimately in an immunologically mediated therapy.

© 2008 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Review

Received: September 19, 2007
Accepted: November 02, 2007
Published online: January 08, 2008
Issue release date: February 2008

Number of Print Pages: 9
Number of Figures: 3
Number of Tables: 1

ISSN: 1420-4096 (Print)
eISSN: 1423-0143 (Online)

For additional information: http://www.karger.com/KBR

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.